跳到正文
原文
Nature Medicine· Marina C. Garassino·· 9 天前AI 评分55

TROP2膜归一化比值作为非小细胞肺癌患者使用datopotamab deruxtecan疗效预测的生物标志物

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

AI 导读

研究开发并验证了TROP2的膜归一化比值作为预测datopotamab deruxtecan疗效的生物标志物,适用于非鳞状非小细胞肺癌患者。

正文

Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04716-9

This work developed and validated a computational pathology biomarker—the TROP2 normalized membrane ratio—that quantifies subcellular TROP2 localization and predicts improved progression-free and overall survival with datopotamab deruxtecan in patients with nonsquamous non-small-cell lung cancer lacking actionable genomic alterations.

来源:Nature Medicine · nature.com